natgillin/translations-raw huggingface dataset:
The antibody drug conjugate of any one of claims 1-5, wherein the anti-DLL3 antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 212 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 213. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 5, naznačen time, da protutijelo anti-DLL3 obuhvaća varijabilno područje slabog lanca koje obuhvaća aminokiselinsku sekvencu prema SEQ ID NO:212 1 varijabilno područje jakog lanca koje obuhvaća aminokiselinsku sekvencu prema SEQ ID NO:213.
The crystalline form of claims 1-4 further characterized by a powder x-ray diffraction pattern comprising four or more of 29 values (CuKa λ=1.5418Å) selected from 5.5, 9.1, 12.1, 14.0 and 19.2 at a temperature of about 22°C. 
Kristalni oblik prema zahtjevima 1-4, dalje naznačen time što obrazac difrakcije rendgenskog zračenja na prašku obuhvaća četiri ili više 20 values (CuKa 2=1.5418 A) izabrane između 5.5, 9.1, 12.1, 14.0 i 19.2 pri temperaturi od oko 22*C.
A light source as claimed in any one of claims 1 to 11, wherein the antenna is a rod or wire of conductive metal extending within a re-entrant in the plasma crucible and the connection is an integral extension of the antenna rod or wire and preferably the void is small in comparison with a distance within the plasma crucible from the Faraday cage at one side or end and to the opposite side or end and the re-entrant is along side or in line with the void. 
Svjetlosni izvor u skladu s bilo kojim patentnim zahtjevom od 1 do 10, naznačen time, da je antena šipka ili žica provodljivog metala koja se proteže u udubljenju u plazmenoj retorti, a priključak je cjeloviti nastavak antenske šipke ili žice.
in two or more doses; and/or 
(a) udvijeili više doza; i/ili
The kit of claim 13, wherein the EO-PO block copolymer is poloxamer 407 (Pluronic F127) and the concentration of the EO-PO block copolymer is about 0.063 % to about 2.0 % (w/v). 
Oprema sukladno patentnom zahtjevu 13, gdje je EO-PO blok kopolimera poloksamer 407 (pluronski F127) i koncentracija EO-PO bloka kopolimera je od otprilike 0,063 % do otprilike 2,0 % (m/V).
A peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 214, 196, 202, 210, 213, 217 and 223 in which 1 or 2 amino acids are substituted, or added, wherein said peptide induces a cytotoxic T cell specific to a cell expressing KNTC2. 
Peptid od manje od 15 aminokiselina koja može inducirati citotoksične T-stanice, gdje navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO: 30, 19, 22, 34, te 358, u kojem su 1 ili 2 aminokiseline zamijenjene, izbačene ili dodane, naznačen time što navedeni peptid inducira citotoksične T-limfocite specifične za stanicu koja eksprimira CDH3.
x is as defined in claim 2, and y is 0.5 to 5. 
AMSDJ, HOI, Formula 11 pri čemu X je definiran u patentnom zahtjevu 2, i Yje0.5do5.
In accordance with the present invention a compound of formula (I) is provided or a pharmaceutically acceptable salt, tautomer(s), solvate or polymorph thereof, wherein 
Spoj formulom (I) Ri II hi N" *NH, R ili njegova farmaceutski prihvatljiva sol, tautomer(i), solvat ili polimorf, naznačen time što
A process according to claim 8 wherein X is introduced in reaction with pyridine and the compound of formula VII is 
Postupak prema zahtjevu 8 naznačen time da se X uvodi u reakciju sa piridinom i spoj sa formulom VII je
Inhibition of human monocyte and platelet adhesion to human endothelial cells 
Inhibicija adhezije humanih monocita 1 trombocita na humane endotelne stanice
The formulation according to any of claims 1 to 13, which is for subcutaneous administration. 
Formulacija prema zahtjevu 10 1li 11, naznačena time da je za potkožno davanje.
Olopatadine nasal spray as in claim 1, 2 or 3 wherein the first amount and second amount are both at least about 1.1 mg. 
Olopatadin nazalni sprej u skladu s patentnim zahtjevom 1, 2 ili 3, naznačen time što su i prva i druga količina najmanje otprilike 1,1 mg.
c.) reacting a salt of a compound of formula III -formed with an organic or inorganic base- by eliminating the acetonide group and reacting with calcium-chloride in a base. 
F - stvorene s organskom ili anorganskom bazom - uz eliminiranje acetonidne skupine i reagiranje s kalcij-kloridom u bazi.
Thus, in a first aspect, the invention provides a method for targeting an antigen to an antigen presenting cell, comprising contacting the antigen presenting cell with a composition comprising the antigen, wherein the antigen is associated with a binding agent having affinity for CLEC9a, and wherein the antigen presenting cell expresses CLEC9a. 
HR P20160033 T1 PATENTNI ZAHTJEVI Sastav, naznačen time, da obuhvaća antigen peptida, pri čemu je antigen kovalentno spojen na protutijelo koje ima afinitet za CLEC9a ili na njegov funkcionalni fragment koji ima afinitet za CLECY9a, i gdje spomenuti sastav opcijski nadalje obuhvaća farmaceutski prihvatljiv nosač.
The method of claim 1, wherein the inflammatory bowel disease is ulcerative colitis. 
Spoj za uporabu prema zahtjevu 11, naznačen time što je bolest ulcerozni kolitis.
In some embodiments, the hemihydrate has a thermogravimetric analysis profile showing about 3.7% weight loss corresponding to loss of water. 
Hemihidrat u skladu sa zahtjevom 1, naznačen time, da ima profil termogravimetrijske analize koji pokazuje gubitak mase oko 3.7% ispod oko 150*C.
selecting, based on said profile information, a plurality of groups of said electric devices located within said geographical area, each said group comprising a plurality of said electric devices; 
odabira (804), na temelju navedenih informacija o profilu, većeg broja skupina navedenih električnih uređaja (208) smještenih unutar navedenog geografskog područja, te svaka navedena skupina sadrži mnoštvo navedenih električnih uređaja (208);
It is a further object of the present invention to provide packaging for CD or DVD's having an improved strength and more exclusive look than known packaging. 
Nadalje je cilj predmetnog izuma taj, da se osigura pakiranje za CD ili DVD koje ima poboljšanu čvrstoću i ekskluzivniji izgled od poznatih pakiranja.
A compound according to any of claims 1 to 5 or a pharmaceutical composition according to claim 7 or 8 for use in the treatment of a cancer selected from the group comprising cancer of the breast, bladder, bone, brain, central and peripheral nervous system, colon, endocrine glands, esophagus, endometrium, germ cells, head and neck, kidney, liver, lung, larynx and hypopharynx, mesothelioma, sarcoma, ovary, pancreas, prostate, rectum, renal, small intestine, soft tissue, testis, stomach, skin, ureter, vagina and vulva; inherited cancers, retinomblastoma and Wilms tumor; leukemia, lymphoma, non-Hodgkins disease, chronic and acute myeloid leukaemia, acute lymphoblastic leukemia, Hodgkins disease, multiple myeloma and T-cell lymphoma; myelodysplastic syndrome, plasma cell neoplasia, paraneoplastic syndromes, cancers of unknown primary site and AIDS related malignancies. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, ili farmaceutski pripravak u skladu s patentnim zahtjevom 9 ili 10, naznačen time što je namijenjen upotrebi u liječenju raka, koji se biraju iz skupine koju čine rak dojke, mokraćnog mjehura, kostiju, mozga, središnjeg i perifernog živčanog sustava, debelog crijeva, endokrinih žlijezda, jednjaka, endometrija, germinativnih stanica, glave i vrata, bubrega, jetre, pluća, grkljana i hipofarinksa, mezoteliom, sarkom, rak jajnika, gušterače, prostate, rektuma, bubrežnih stanica, tankog crijeva, mekih tkiva, testisa, želuca, kože, mokraćovoda, vagine i vulve; nasljedni oblici raka, retinomblastom i Wilmsov tumor; leukemija, limfom, ne-Hodgkinova bolest, kronična i akutna mijeloidna leukaemija, akutna limfoblastična leukemija, Hodgkinova bolest, multipli mijelom i T-stanični limfom; mijelodisplastični sindrom, plazmacitne novotvorine, paraneoplastični sindromi, rak nepoznatog primarnog sijela i malignomi povezani s AIDS-om.
The composition for the use of claim 18 or claim 19, wherein the biodegradable implant delivers a therapeutically effective dosage of the buprenorphine from 0.1 to 10 milligrams (mg) or 1 to 5 milligrams (mg) per day. 
Pripravak za primjenu sukladno zahtjevu 18 ili zahtjevu 19, pri čemu biorazgradivi implantat daje terapeutski učinkovitu dozu buprenorfina od 0.1 do 10 miligrama (mg) ili 1 do 5 miligrama (mg) po danu.
The polystyrene of claim 1, wherein the adsorbent exhibits a surface area of at least 90 m2/g. 
Polistiren sukladno zahtjevu 1, naznačeno time da adsorbent ima površinu od najmanje 90m2/g.
and R14 are independently H, C1-C6 alkyl, aryl, or arylalkyl or R13 and R14 can combine to form a fused phenyl, thienyl, pyrrolyl, cyclopentyl or cyclohexyl ring; wherein the phenyl, thienyl, pyrrolyl, cyclopentyl or cyclohexyl rings are optionally substituted with 1 to 3 R20 groups; 
i R14 predstavljaju nezavisno H, (C1-C6)alkil, aril ili arilalkil ili se R13 i R14 mogu kombinirati kako bi formirali fuzionirani fenilni, tienilni, pirolilni, ciklopentilni ili cikloheksilni prsten; gdje fenilne, tienilne, pirolilne, ciklopentilne ili cikloheksilne prstene opcionalno supstituiraju 1 do 3 R20 skupine;
A pharmaceutical composition according to claim 8 for use in the treatment of pathological angiogenesis. 
Farmaceutski pripravak sukladno patentnom zahtjevu 8, radi liječenja patološke angiogeneze.
This increased heat transfer makes more efficient use of the available fuel energy, reduces the amount of fuel needed, and helps deliver early aerosol. 
Ovaj povećan prijenos topline omogućuje efikasnije korištenje energije pristupačnog goriva, smanjuje količinu potrebnog goriva i pomaže ranu isporuku aerosola.
The antibody drug conjugate for use according to any one of claims 1-20, wherein the anti-DLL3 antibody is selected from the group consisting of a monoclonal antibody, chimeric antibody, CDR-grafted antibody, humanized antibody, human antibody, primatized antibody, multispecific antibody, bispecific antibody, monovalent antibody, multivalent antibody, diabody, Fab fragment, F(ab')2 fragment, Fv fragment, and ScFv fragment; or an immunoreactive fragment thereof. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je protutijelo anti-DLL3 odabrano iz skupine koju čine monoklonalno protutijelo, kimerno protutijelo, CDR-cijepljeno protutijelo, humanizirano protutijelo, ljudsko protutijelo, primatizirano protutijelo, multispecifično protutijelo, bispecifično protutijelo, monovalentno protutijelo, multivalentno protutijelo, diabody, Fab-fragment, F(ab'),-fragment, Fv- fragment i ScFv-fragment; ili njegov imunoreaktivni fragment koji se specifično veže na epitop unutar DSL-domene od DLI.3-proteina prema SEQ ID NO:3 ili SEQ ID NO:4.
• when RCG1 represents a -OH or -NH2 group, RCG2 represents a carboxylic acid or amide function; 
* kada RCGI predstavlja skupinu -OH ili -NH2, RCG2 predstavlja karboksilnu kiselinu ili amidnu funkciju;
A chimeric peptide consisting of a first domain, a second domain and optionally a linker sequence, the first domain consisting of a trafficking sequence and the second domain consisting of a JNK inhibitor sequence, wherein the first domain consists of the all-D retro-inverso amino acid sequence according to SEQ ID NO:6 and wherein the second domain consists of the all-D retro-inverso amino acid sequence according to SEQ ID NO:2, wherein the first domain is linked to the C-terminal end of the second domain either directly or by said linker sequence consisting of 1 to 10 amino acids. 
Kimerni peptid koji sadrži prvu domenu, drugu domenu i proizvoljno vezujuću sekvencu, te prva domena sadrži transportnu sekvencu i druga domena sadrži JNK inhibicijsku sekvencu, naznačen time da prva domena sadrži sve-D retro-inverzo sekvence amino kiseline u skladu sa SEQ ID NO:6 te time da druga domena sadrži sve-D retro-inverzo sekvence amino kiseline u skladu sa SEQ ID NO:2, pri čemu je prva domena vezana na C-terminalni kraj druge domene bilo izravno ili pomoću navedene vezujuće sekvence koja sadrži 1 do 10 amino kiselina.
The method of claim 10, wherein the chimerized antibody comprises a heavy chain constant region having an amino acid sequence represented by SEQ ID NO: 150 and a light chain constant region having an amino acid sequence represented by SEQ ID NO: 41. 
sekvence nukleinske kiseline koja kodira polipeptid koji sadrži varijabilno područje teškog lanca koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 133 i varijabilno područje lakog lanca koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 138; i
A pharmaceutical composition comprising Compound 1. Compound 1 for use as a medicament. 
2. Spoj prema patentnom zahtjevu 1, za uporabu kao lijek.
and X12 are independently a natural or unnatural amino acid selected from C, c, hC, D-hC, K, D, Orn, Dab or E wherein the side chain of X6 and X12 are linked together via a covalent bond; and wherein the N-terminus and the C-terminus optionally form a ring together with 1, 2, 3 or 4 glycine amino acids; or an amide, an ester or a salt of the polypeptide; or a polypeptide substantially equivalent thereto. 
X6 i X12 su neovisno prirodna ili neprirodna amino kiselina odabrana od €, c, hC, D-hC, pri čemu su bočni lanci od X6 i X12 međusobno povezani preko kovalentne veze koja tvori disulfid; te time, da N-terminalni kraj i C-terminalni kraj opcijski tvore prsten zajedno s 1, 2, 3 ili 4 glicinskih amino kiselina; ili amid, ester ili sol polipeptida; dok pritom Nle je L-norleukin, D-hC je D-homocistein; hC je L-homocistein;
Accordingly, the image data decoder 230 may decode encoded data of at least one coding unit corresponding to the each coded depth in the current maximum coding unit by using the information about the partition type of the prediction unit, the prediction mode, and the size of the transformation unit for each coding unit corresponding to the coded depth, and output the image data of the current maximum coding unit. 
- < ekstraktor (220) podešen tako, da iz toka bitova izvlači informaciju o maksimalnoj veličini kodirajuće jedinice, koja je jedinica podataka u kojoj je kodirana slika, informaciju o maksimalnoj dubini, koja označava ukupni broj mogućih dijeljenja maksimalne kodirajuće jedinice i informaciju o dubini kodiranja i načinu kodiranja jedinica slike;
A therapeutically effective amount of a composition comprising laminin-1 and a chelating agent for use in promoting wound healing in a subject wherein the composition is to be administered systemically. 
Neka terapeutski djelotvorna količina laminina-1 za pospješivanje zacjeljivanja rane kod neke osobe, naznačena time da se taj laminin-1 primjenjuje sistemski.
in Formula 12 and Formula 13 is as defined above in Formula 4 and 5. 
R!, R*iR* u Formuli 4 i Formuli 5 su definirani kao za Formulu 3;1
is H, C(1-5)alkyl, wherein said C(1-5)alkyl is optionally substituted with one to two substituents independently selected from CONH2, -CN, and OH; and pharmaceutically acceptable salts thereof. 
N=9 Ze OH odao pri čemu spomenuti Ca-syalkil je po potrebi supstituiran sa jednim do dva supstituenata nezavisno izabranih od CONN, -CN, 1 OH; i njihovih farmaceutski prihvatljivih soli.
A method for the conversion of compound of formula B-(4) into the compound of formula a-(4) which comprises an epimerization with acid. 
Postupak za pretvorbu spoja s formulom B-(4) u spoj s formulom a-(4) naznačen time da sadrži epimerizaciju s kiselinom [image] .
The compound according to claims 22 or 23, or the pharmaceutically acceptable salt thereof or the solvate thereof, wherein R7a is a group shown below: (wherein RE6 and m are same as those of claim 13). 
Spoj prema zahtjevima 22 ili 23, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat, naznačen time, da R" je skupina prikazana dolje: HR P20180885 T1 iKemnska formula 6] m o Na
Gradient: 5% to 55% methanol over 1.7 min and hold at 55% for 0.8 min then return to 5% in 0.1 min for total run time of 2.6 min Method 2 (HPLC-MS) 
Gradijent: 5 % do 55 % metanola u trajanju od 1,7 minuta, uz održavanje na 55 % 0,8 minuta, te ponovno do 5 % 0,1 minutu, uz ukupno vrijeme trajanja od 2,6 minuta. Postupak 2
An oxycodone salt composition comprising an oxycodone salt and 14-hydroxycodeinone in an amount of less than 25 ppm. 
Postupak prema zahtjevu 1, naznačen time da rezultantni sastav oksikodon hidroklorida sadrži 14-hidroksikodeinon u količini manjoj od 10 ppm.
is hydrogen or methyl. A compound of claim 19, wherein G2 is selected from the group below: 
Spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time da je G, izabran iz skupine ispod:
A method for inhibiting VR1 function in a cell comprising contacting a cell, capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1 or claim 10. 
Postupak za inhibiranje VRI funkcije u stanici in vitro naznačen time da sadrži kontaktiranje stanice, koja može izražavati VRI1, sa učinkovitom količinom spoja ili farmaceutski prihvatljivo soli spoja prema zahtjevu 1 ili zahtjevu 20.
In the discharge state, the user has full control over discharging of the contents of the metering chamber 6 by depressing the actuation member 17 from the intermediate position to the second position as many times as it takes to empty the metering chamber 6 . 
U stanju pražnjenja, korisnik ima punu kontrolu nad sadržajem pražnjenja iz odmjerne komore 6 pritiskom na element za pokretanje 17 iz međupoložaja u drugi položaj toliko puta koliko je potrebno da isprazni odmjernu komoru 6.
wherein the first integrated circuitry comprises at least one secure processing unit adapted to process the sensitive data, wherein the first integrated circuitry is separated from the second integrated circuitry, 
- najmanje jednu sigurnosnu procesorsku jedinicu (11), prilagođena za obradu osjetljivih podataka, gdje je prvi integrirani krug (10) odvojen od drugog integriranog kruga (20);
What is vital is that each subunit contains the polymer (C) and has been formulated in the stated manner. 
Odlučujuće je, da dotične podjedinice sadrže polimer (C) i po potrebi komponentu (D) i da su formulirane na prethodno navedeni način.
International Publication No. 
Datum međunarodne objave:
A process for obtaining a pharmaceutical composition containing a mixture of polypeptides which do not all have the same amino acid sequence, where each polypeptide consists essentially of alanine, glutamic acid, tyrosine and lysine, and wherein the mixture has a desired average molecular weight, which comprises 
Postupak za dobivanje farmaceutskog sastava koji sadrži smjesu glatiramer acetata i u čemu smjesa ima željenu prosječnu molekularnu težinu, naznačen time, da obuhvaća:
The conjugated nucleic acid molecule for use according to claim 8, in combination with radiotherapy or chemotherapy, optionally with a DNA damaging antitumoral agent. 
Konjugirana molekula nuklemske kiseline naznačena time što je namijenjena upotrebi u skladu s patentnim zahtjevom 8, u kombinaciji s radioterapijom ili kemoterapijom, izborno s protutumorskim sredstvom koje oštećuje DNA.
wherein, when a prediction mode is determined to be an inter prediction mode, not an intra prediction mode, the apparatus (500, 1500) for decoding the image is configured to support a transformation unit, included among the at least one transformation unit, having a size of 2N x 2N, that includes four prediction units included among the at least one prediction unit and having a size of N x N. 
kvantizirane koeficijente transformacije za najmanje jednu transformacijsku jedinicu generirane provođenjem inter predviđanja za barem jednu jedinicu predviđanja u jedinici za kodiranje radi generiranja predviđatelja i provođenje transformacije i kvantizacije na temelju predviđatelja i slike;
(The sealing member can also cover only a portion of the side wall 7 of the base body 4 of the capsule 1.) 
(Element za nepropusno zatvaranje može također prekrivati samo predio bočne stijenke 7 osnovnog tijela 4 čahure 1.)
and R2 taken together with the carbon atoms to which they are attached form a C5–C8cyclic ring; and m is 1 or 2. 
R, i R2 zajedno s ugljikovim atomima na koje su pričvršćeni oblikuju Cs-Ca ciklički prsten; i m je 1 ili 2.
100 l/well HRP-conjugate were added to the plates and incubated for 1 hour at 37° C. with shaking. 
100 ul /bunariću HRP konjugata je potom dodano u pločice i inkubirano 1 sat na 37 "C uz potresanje.
applying the immunoglobulin solution to a combination of a first and second filter unit, whereby the first filter unit comprises a pre-filter with a pore size of 3.0 µm and a main-filter with a pore size of 0.8 µm and the second filter unit comprises a pre-filter with a pore size of 0.45 µm and a main-filter with a pore size of 0.22 µm with a pressure of from 0.1 to 4.0 bar, and thereby producing an immunoglobulin solution. 
nanošenje otopine imunoglobulina na kombinaciju prve i druge filterske jedinice, pri čemu prva filterska jedinica sadrži predfilter s veličinom pora od 3,0 um i glavni filter s veličinom pora od 0,8 um, a druga filterska jedinica sadrži predfilter s veličinom pora od 0,45 um i glavni filter s veličinom pora od 0,22 um, s tlakom od 0,1 do 4,0 bara, te se time proizvodi otopina imunoglobulina.
The amount of water in the obtained tablets was 5.3 % by weight, determined by the Karl-Fischer method which was performed according to Ph. Eur. 
Količina vode u dobivenim tabletama određena je Karl Fischerovom metodom i iznosila je 5,3 % težine.
updating the first and/or second routing table depending on control data being exchanged between the first and second virtual provider edge (vPE) appliances (41,42). 
ažuriranje prve i/ili druge tablice usmjeravanja, ovisno o kontrolnim podacima koji se izmjenjuju između prvog i drugog uređaja virtualnog pružatelja usluga (vPE) (41, 42).
A capsule for oral administration comprising a composition according to claim 1 wherein the surfactant is selected from the group consisting of Macrogolglycerol hydroxystearate, Caprylocaproyl Macrogol-8 glycerides, Vitamin E Polyethylene Glycol Succinate and Glyceryl caprylate. A capsule for oral administration comprising the composition according to claim 1 which contains from about 50 to about 400 mg alisporivir. 
Kapsula za oralnu primjenu prema bilo kojem od zahtjeva 2 do 7, naznačena time, da farmaceutski sastav obuhvaća tenzid koji je odabran iz skupine koju čine makrogolglicerol-hidroksistearat, kaprilokaproil-makrogol-8-gliceridi, vitamin E-polietilenglikol-sukcinat i gliceril-kaprilat, a poželjno je odabran iz skupine koju čine makrogolglicerol-hidroksistearat, kaprilokaproil-makrogol-8-gliceridi i vitamin E-polietilenglikol-sukcinat.
deprotecting the boronic acid moiety to form a boronic acid anhydride of the compound of formula (XIV). 
uklanjanja zaštitne grupe P1da se formira spoj formule (XXI):